SCHEMBL1944141

SCHEMBL1944141

COCCNc1nn2cc(-c3ccccc3N(C)C)nc2s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 11/20 0.42
SMN1; SMN2 Q16637 6/20 0.38
TP53 P04637 4/20 0.38
MAPT P10636 3/20 0.38
RAB9A P51151 5/20 0.36
NPC1 O15118 4/20 0.36
KDM4E B2RXH2 3/20 0.36
HSD17B10 Q99714 1/20 0.36
RECQL P46063 2/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
ALOX15 P16050 2/20 0.36
PKM P14618 1/20 0.36
NFKB1 P19838 2/20 0.35
NFKB2 Q00653 2/20 0.35
RELA Q04206 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1946225 0.89 NPC1 (0.40) F2RL3SMN1; SMN2TP53MAPTRAB9A
SCHEMBL1945976 0.85 F2RL3 (0.61) F2RL3SMN1; SMN2TP53MAPTRAB9A
SCHEMBL1944082 0.83 F2RL3 (0.42) F2RL3SMN1; SMN2TP53MAPTRAB9A
SCHEMBL1945123 0.83 NPC1 (0.40) F2RL3SMN1; SMN2TP53MAPTRAB9A
SCHEMBL1947356 0.82 FYN (0.43) F2RL3SMN1; SMN2TP53MAPTRAB9A
SCHEMBL1947874 0.82 F2RL3 (0.57) F2RL3SMN1; SMN2TP53MAPTRAB9A
SCHEMBL1945570 0.82 JAK2 (0.39) F2RL3SMN1; SMN2TP53MAPTRAB9A
SCHEMBL1946801 0.79 FYN (0.42) F2RL3SMN1; SMN2TP53MAPTRAB9A
SCHEMBL1944503 0.79 F2RL3 (0.44) F2RL3SMN1; SMN2TP53MAPTRAB9A
SCHEMBL1945096 0.79 FYN (0.41) F2RL3MAPTRAB9ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP claimed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES TGFBR1, TGFBR2, IGF1R F2RL3 1121/4885SMN1; SMN2 4370/4885TP53 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.